ACADIA PHARMACEUTICALS INC (ACAD) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for ACADIA PHARMACEUTICALS INC (ACAD): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 66/100 — a percentile rank of ACADIA PHARMACEUTICALS INC’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $3.5B |
| P / E | 9.1× |
| P / S | 3.0× |
| EV / EBITDA | 33.2× |
| Gross margin | 91.1% |
| Operating margin | 7.6% |
| Net margin | 33.4% |
| Return on equity | 29.1% |
| ROIC | 29.4% |
| Revenue growth | 11.8% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is ACADIA PHARMACEUTICALS INC overvalued? P/E looks fair vs its 5-year range; P/S looks undervalued vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks undervalued vs its 5-year range.
Independent of the events above — derived from ACADIA PHARMACEUTICALS INC’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact